242 related articles for article (PubMed ID: 24308789)
21. Paediatric investigation plans for pain: painfully slow!
Davies EH; Ollivier CM; Saint Raymond A
Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
[TBL] [Abstract][Full Text] [Related]
22. Challenges of developing palatable oral paediatric formulations.
Cram A; Breitkreutz J; Desset-Brèthes S; Nunn T; Tuleu C;
Int J Pharm; 2009 Jan; 365(1-2):1-3. PubMed ID: 18848611
[No Abstract] [Full Text] [Related]
23. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
Carleer J; Karres J
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
[TBL] [Abstract][Full Text] [Related]
24. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
25. Paediatric formulations--getting to the heart of the problem.
Standing JF; Tuleu C
Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
[TBL] [Abstract][Full Text] [Related]
26. Role of modeling and simulation in pediatric investigation plans.
Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
[TBL] [Abstract][Full Text] [Related]
27. European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary--Formulating better medicines for children.
Salunke S; Hempenstall J; Kendall R; Roger B; Mroz C; Nunn T; Tuleu C
Int J Pharm; 2011 Oct; 419(1-2):235-9. PubMed ID: 21784141
[No Abstract] [Full Text] [Related]
28. Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference.
Walsh J; Mills S
Ther Deliv; 2013 Jan; 4(1):21-5. PubMed ID: 23323778
[TBL] [Abstract][Full Text] [Related]
29. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework.
Manolis E; Pons G
Br J Clin Pharmacol; 2009 Oct; 68(4):493-501. PubMed ID: 19843052
[TBL] [Abstract][Full Text] [Related]
30. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
Thabet Y; Klingmann V; Breitkreutz J
J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
[TBL] [Abstract][Full Text] [Related]
31. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
[TBL] [Abstract][Full Text] [Related]
32. Developing paediatric medicines: identifying the needs and recognizing the challenges.
Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
[TBL] [Abstract][Full Text] [Related]
33. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Rocchi F; Tomasi P
Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
[TBL] [Abstract][Full Text] [Related]
34. Regulatory perspectives on acceptability testing of dosage forms in children.
Kozarewicz P
Int J Pharm; 2014 Aug; 469(2):245-8. PubMed ID: 24704104
[TBL] [Abstract][Full Text] [Related]
35. Patent landscape of pediatric-friendly oral dosage forms and administration devices.
Karavasili C; Gkaragkounis A; Fatouros DG
Expert Opin Ther Pat; 2021 Jul; 31(7):663-686. PubMed ID: 33605825
[TBL] [Abstract][Full Text] [Related]
36. Rectal route in the 21st Century to treat children.
Jannin V; Lemagnen G; Gueroult P; Larrouture D; Tuleu C
Adv Drug Deliv Rev; 2014 Jun; 73():34-49. PubMed ID: 24871671
[TBL] [Abstract][Full Text] [Related]
37. 10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
Thabet Y; Slavkova M; Breitkreutz J
Expert Opin Drug Deliv; 2018 Mar; 15(3):261-270. PubMed ID: 29284286
[TBL] [Abstract][Full Text] [Related]
38. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
39. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study.
Venables R; Batchelor H; Stirling H; Marriott J
Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666
[TBL] [Abstract][Full Text] [Related]
40. [Are children getting the right drugs?].
Bratlid D
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
